白血病·淋巴瘤
白血病·淋巴瘤
백혈병·림파류
Journal of Leukemia & Lymphoma
2015年
10期
598-600
,共3页
吴少杰%涂三芳%郑雅玲%王磊%宋朝阳
吳少傑%塗三芳%鄭雅玲%王磊%宋朝暘
오소걸%도삼방%정아령%왕뢰%송조양
淋巴瘤,黏膜相关淋巴样组织%复发%利妥昔单抗%苯达莫司汀
淋巴瘤,黏膜相關淋巴樣組織%複髮%利妥昔單抗%苯達莫司汀
림파류,점막상관림파양조직%복발%리타석단항%분체막사정
Lymphoma,mucosa-associated lymphoid tissue%Recurrence%Rituximab%Bendamustine
目的 探讨利妥昔单抗联合苯达莫司汀(R-Benda)治疗胃外复发黏膜相关淋巴组织淋巴瘤(MALT淋巴瘤)的疗效.方法 回顾性分析接受R-Benda方案化疗的10例诊断为复发胃外的MALT淋巴瘤患者临床资料.9例患者分别在化疗第2天和第3天接受90 mg/m2苯达莫司汀,1例患者因体能原因接受70 mg/m2苯达莫司汀;所有患者均在第1天接受375 mg/m2利妥昔单抗治疗;21 d为1个疗程.结果 8例患者接受了6个疗程化疗,1例患者因个人原因仅接受5个疗程化疗,另外1例老年患者在接受3个疗程化疗后疾病进展.8例患者达到了完全缓解,1例患者达到了部分缓解,另外1例老年患者在化疗4个疗程后因疾病进展而死亡.患者主要存在血液学不良反应事件,但程度较轻.中位随访24个月(5~43个月),9例患者生存,其中8例处于疾病缓解期.结论 R-Benda方案治疗胃外复发MALT淋巴瘤疗效好,而且不良反应轻.
目的 探討利妥昔單抗聯閤苯達莫司汀(R-Benda)治療胃外複髮黏膜相關淋巴組織淋巴瘤(MALT淋巴瘤)的療效.方法 迴顧性分析接受R-Benda方案化療的10例診斷為複髮胃外的MALT淋巴瘤患者臨床資料.9例患者分彆在化療第2天和第3天接受90 mg/m2苯達莫司汀,1例患者因體能原因接受70 mg/m2苯達莫司汀;所有患者均在第1天接受375 mg/m2利妥昔單抗治療;21 d為1箇療程.結果 8例患者接受瞭6箇療程化療,1例患者因箇人原因僅接受5箇療程化療,另外1例老年患者在接受3箇療程化療後疾病進展.8例患者達到瞭完全緩解,1例患者達到瞭部分緩解,另外1例老年患者在化療4箇療程後因疾病進展而死亡.患者主要存在血液學不良反應事件,但程度較輕.中位隨訪24箇月(5~43箇月),9例患者生存,其中8例處于疾病緩解期.結論 R-Benda方案治療胃外複髮MALT淋巴瘤療效好,而且不良反應輕.
목적 탐토리타석단항연합분체막사정(R-Benda)치료위외복발점막상관림파조직림파류(MALT림파류)적료효.방법 회고성분석접수R-Benda방안화료적10례진단위복발위외적MALT림파류환자림상자료.9례환자분별재화료제2천화제3천접수90 mg/m2분체막사정,1례환자인체능원인접수70 mg/m2분체막사정;소유환자균재제1천접수375 mg/m2리타석단항치료;21 d위1개료정.결과 8례환자접수료6개료정화료,1례환자인개인원인부접수5개료정화료,령외1례노년환자재접수3개료정화료후질병진전.8례환자체도료완전완해,1례환자체도료부분완해,령외1례노년환자재화료4개료정후인질병진전이사망.환자주요존재혈액학불량반응사건,단정도교경.중위수방24개월(5~43개월),9례환자생존,기중8례처우질병완해기.결론 R-Benda방안치료위외복발MALT림파류료효호,이차불량반응경.
Objective To investigate the rituximab plus bendamustine (R-Benda) therapeutic effect for relapsed extragastric mucosa-associated lymphoid tissue (MALT) lymphoma.Methods Ten patients (three females and seven males) with relapsed extragastric MALT lymphoma undergoing therapy with R-Benda were defined.Bendamustine was given at a dose of 90 mg/m2 on days 2 and 3 in nine patients and at 70 mg/m2 in one patient, while all received 375 mg/m2 rituximab on day 1.Results Nine patients received six courses of therapy,while one patient discontinued therapy after five courses for personal reasons, while one elderly patient had progressive disease after three courses.Tolerance of therapy was excellent, and all except one patient responded.Eight patients achieved the complete remission, one achieved the partial remission, and one patient progressed.Toxicities were mild and mainly hematological.After a median follow-up of 24 months (range, 5-43 months), 9 patients were alive.Conclusion R-Benda regime has high activity and good tolerance for patients with relapsed extragastric MALT lymphoma.